$ 3.07 Million in Sales Expected for KemPharm, Inc. (NASDAQ: KMPH) This Quarter


Wall Street brokerages predict that KemPharm, Inc. (NASDAQ: KMPH – Get Rating) will post $ 3.07 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for KemPharm’s earnings. The lowest sales estimate is $ 2.00 million and the highest is $ 4.13 million. KemPharm posted sales of $ 12.12 million in the same quarter last year, which would indicate a negative year over year growth rate of 74.7%. The company is scheduled to issue its next quarterly earnings report after the market closes on Monday, January 1st.

According to Zacks, analysts expect that KemPharm will report full-year sales of $ 20.82 million for the current financial year, with estimates ranging from $ 16.22 million to $ 25.42 million. For the next fiscal year, analysts anticipate that the firm will post sales of $ 47.86 million, with estimates ranging from $ 25.97 million to $ 69.76 million. Zacks’ sales averages are an average based on a survey of analysts that follow KemPharm.

KemPharm (NASDAQ: KMPH – Get Rating) last posted its quarterly earnings data on Wednesday, March 30th. The specialty pharmaceutical company reported ($ 0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($ 0.08). KemPharm had a positive return on equity of 7.03% and a negative net margin of 29.86%.

Several brokerages have commented on KMPH. StockNews.com began coverage on shares of KemPharm in a research report on Thursday, March 31st. They set a “hold” rating for the company. HC Wainwright upgraded shares of KemPharm from a “neutral” rating to a “buy” rating and upped their target price for the company from $ 10.00 to $ 11.00 in a research report on Monday, January 31st. Finally, Zacks Investment Research upgraded shares of KemPharm from a “sell” rating to a “hold” rating in a research report on Wednesday.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC bought a new stake in shares of KemPharm in the 4th quarter valued at $ 26,000. Citigroup Inc. increased its position in shares of KemPharm by 139.5% in the 3rd quarter. Citigroup Inc. now owns 3,257 shares of the specialty pharmaceutical company’s stock valued at $ 30,000 after buying an additional 1,897 shares in the last quarter. Advisor Group Holdings Inc. increased its position in shares of KemPharm by 357.2% in the 3rd quarter. Advisor Group Holdings Inc. now owns 4,535 shares of the specialty pharmaceutical company’s stock valued at $ 42,000 after buying an additional 3,543 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in shares of KemPharm in the 1st quarter valued at $ 66,000. Finally, City State Bank bought a new stake in shares of KemPharm in the 4th quarter valued at $ 71,000. Institutional investors and hedge funds own 32.39% of the company’s stock.

NASDAQ: KMPH opened at $ 4.24 on Friday. The stock’s fifty day moving average price is $ 4.84 and its two-hundred day moving average price is $ 6.75. KemPharm has a 52-week low of $ 4.00 and a 52-week high of $ 15.70.

About KemPharm (Get Rating)

KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.

See Also

Get a free copy of the Zacks research report on KemPharm (KMPH)

For more information about research offers from Zacks Investment Research, visit Zacks.com



Receive News & Ratings for KemPharm Daily – Enter your email address below to receive a concise daily summary of the latest news and analyzes’ ratings for KemPharm and related companies with MarketBeat.com’s FREE daily email newsletter.

.

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker